{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:54:56Z","timestamp":1792713296184,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40744-023-00563-z","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T06:02:38Z","timestamp":1686290558000},"page":"969-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0257-1061","authenticated-orcid":false,"given":"Emine","family":"Duran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-163X","authenticated-orcid":false,"given":"Zeynep Ozge","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-4660","authenticated-orcid":false,"given":"Emre","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4764-2348","authenticated-orcid":false,"given":"Yahya","family":"B\u00fcy\u00fcka\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-9078","authenticated-orcid":false,"given":"Omer","family":"Dizdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9543-4685","authenticated-orcid":false,"given":"Gozde Kubra","family":"Yardimci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-1103","authenticated-orcid":false,"given":"Bayram","family":"Farisogullari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3274-3258","authenticated-orcid":false,"given":"Zehra","family":"\u00d6zsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1889-9619","authenticated-orcid":false,"given":"Gizem","family":"Ayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5010-9114","authenticated-orcid":false,"given":"Gullu Sandal","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8757-6226","authenticated-orcid":false,"given":"Mustafa","family":"Ekici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdinc","family":"Unaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-9690","authenticated-orcid":false,"given":"Levent","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-9144","authenticated-orcid":false,"given":"Ali","family":"Akdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3117","authenticated-orcid":false,"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8208-1585","authenticated-orcid":false,"given":"\u015eule Apra\u015f","family":"Bilgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-6061","authenticated-orcid":false,"given":"Sedat","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-2109","authenticated-orcid":false,"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-0769","authenticated-orcid":false,"given":"Ali Ihsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"issue":"2","key":"563_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244\u201379.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"563_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2217\/imt.10.67","volume":"2","author":"LC Silva","year":"2010","unstructured":"Silva LC, Ortigosa LC, Benard GJI. Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2(6):817\u201333.","journal-title":"Immunotherapy"},{"issue":"1","key":"563_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, et al. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27(1):55\u201362.","journal-title":"Int Immunol"},{"issue":"10","key":"563_CR4","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/ard.2004.033241","volume":"64","author":"J Askling","year":"2015","unstructured":"Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2015;64(10):1414\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"563_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","volume":"9","author":"FB Pallavicini","year":"2010","unstructured":"Pallavicini FB, Caporali R, Sarzi-Puttini P, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev. 2010;9(3):175\u201380.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"563_CR6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3892\/ol.2017.6368","volume":"14","author":"CC Chang","year":"2017","unstructured":"Chang CC, Chang CW, Nguyen PA, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett. 2017;14(2):1315\u201322.","journal-title":"Oncol Lett"},{"key":"563_CR7","unstructured":"Lee E, Han K-D, Song Y-W, et al. Cancer risk in patients with ankylosing spondylitis: a nationwide population-based dynamic cohort study from Korea. In: Arthritis & rheumatology. Hoboken : Wiley; 2019."},{"issue":"1","key":"563_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11739-015-1270-0","volume":"11","author":"M Fant\u00f2","year":"2016","unstructured":"Fant\u00f2 M, Peragallo MS, Pietrosanti M, et al. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience. Intern Emerg Med. 2016;11(1):31\u201340.","journal-title":"Intern Emerg Med"},{"issue":"5","key":"563_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","volume":"22","author":"KW Hagberg","year":"2016","unstructured":"Hagberg KW, Li L, Peng M, et al. Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol. 2016;22(5):241\u20137.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"563_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","volume":"72","author":"L Dreyer","year":"2013","unstructured":"Dreyer L, Mellemkj\u00e6r L, Andersen AR, et al. Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides\u2014a follow-up study from the DANBIO Registry. Ann Rheum Dis. 2013;72(1):79\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"563_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/art.22579","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433\u20139.","journal-title":"Arthritis Rheum"},{"key":"563_CR12","unstructured":"Greenberg J, Strand V, Keystone E, et al. TNF inhibitors (TNF-I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years (abstract 282). In: American College of Rheumatology annual meeting. 2007."},{"issue":"1","key":"563_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","volume":"76","author":"K Hellgren","year":"2017","unstructured":"Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis. 2017;76(1):105\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"563_CR14","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.4049\/jimmunol.163.10.5358","volume":"163","author":"Y Kashii","year":"1999","unstructured":"Kashii Y, Giorda R, Herberman RB, et al. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol. 1999;163(10):5358\u201366.","journal-title":"J Immunol"},{"issue":"14","key":"563_CR15","first-page":"3404","volume":"59","author":"DM Katschinski","year":"1999","unstructured":"Katschinski DM, Robins HI, Schad M, et al. Role of tumor necrosis factor alpha in hyperthermia-induced apoptosis of human leukemia cells. Cancer Res. 1999;59(14):3404\u201310.","journal-title":"Cancer Res"},{"issue":"3","key":"563_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0952-7915(00)00093-5","volume":"12","author":"G Screaton","year":"2000","unstructured":"Screaton G, Xu XN. T cell life and death signalling via TNF-receptor family members. Curr Opin Immunol. 2000;12(3):316\u201322.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"563_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nrrheum.2017.81","volume":"13","author":"E Nikiphorou","year":"2017","unstructured":"Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017;13(8):503\u201310.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"563_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"563_CR19","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"563_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"563_CR21","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"563_CR22","unstructured":"Turkish National Cancer Registry (TNCR). https:\/\/hsgm.saglik.gov.tr\/tr\/kanser-istatistikleri\/yillar\/2017-turkiye-kanser-i-statistikleri.html. 2017."},{"issue":"5","key":"563_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/ard.2007.085852","volume":"68","author":"J Askling","year":"2009","unstructured":"Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68(5):648\u201353.","journal-title":"Ann Rheum Dis"},{"key":"563_CR24","volume-title":"OP0005 incidence of overall and site-specific cancers in TNF inhibitor treated patients with psoriatic arthritis: a population-based cohort study from 4 Nordic countries","author":"C Ballegaard","year":"2019","unstructured":"Ballegaard C, Hellgren K, Cordtz R, et al. OP0005 incidence of overall and site-specific cancers in TNF inhibitor treated patients with psoriatic arthritis: a population-based cohort study from 4 Nordic countries. London: BMJ Publishing Group Ltd; 2019."},{"issue":"2","key":"563_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301(2):418\u201326.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"563_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","volume":"50","author":"X Mariette","year":"2011","unstructured":"Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford). 2011;50(1):222\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"563_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1365-2796.2008.02029.x","volume":"264","author":"KE Smedby","year":"2008","unstructured":"Smedby KE, Askling J, Mariette X, et al. Autoimmune and inflammatory disorders and risk of malignant lymphomas\u2014an update. J Intern Med. 2008;264(6):514\u201327.","journal-title":"J Intern Med"},{"issue":"3","key":"563_CR28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692\u2013701.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"563_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","volume":"43","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014;43(4):489\u201397.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"563_CR30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","volume":"168","author":"S Bernatsky","year":"2008","unstructured":"Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med. 2008;168(4):378\u201381.","journal-title":"Arch Intern Med"},{"issue":"1","key":"563_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.mayocp.2022.06.030","volume":"98","author":"S Alehashemi","year":"2023","unstructured":"Alehashemi S, Ward MM. Risk of hematologic malignancies in elderly patients with ankylosing spondylitis: a cohort study and systematic review [published correction appears in Mayo Clin Proc. 2023 Feb 13]. Mayo Clin Proc. 2023;98(1):100\u201310.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"563_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","volume":"22","author":"KW Hagberg","year":"2016","unstructured":"Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS. Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol. 2016;22(5):241\u20137.","journal-title":"J Clin Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00563-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00563-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00563-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:38:45Z","timestamp":1779457125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00563-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00563-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"2 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct the ORCID iD of author Zeynep Ozge Ozturk.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}